SCHEMBL433979

SCHEMBL433979

O=C(NC(C(=O)O)C1CCCCC1)OCc1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.56
EPHX1 P07099 1/20 0.55
MEN1 O00255 1/20 0.54
KMT2A Q03164 1/20 0.54
GAA P10253 1/20 0.51
CTSK P43235 2/20 0.49
CTSL P07711 1/20 0.49
CTSB P07858 1/20 0.49
CTSS P25774 1/20 0.49
CYP1A2 P05177 1/20 0.49
TSHR P16473 1/20 0.49
CTRB1 P17538 2/20 0.49
DPP4 P27487 1/20 0.48
KCNH2 Q12809 1/20 0.48
DPP7 Q9UHL4 1/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2C9 P11712 1/20 0.48
CYP2C19 P33261 1/20 0.48
CASP1 P29466 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL433978 1.00 ALDH1A1 (0.56) ALDH1A1EPHX1MEN1KMT2AGAA
SCHEMBL22285592 1.00 ALDH1A1 (0.56) ALDH1A1EPHX1MEN1KMT2AGAA
SCHEMBL22285596 1.00 ALDH1A1 (0.56) ALDH1A1EPHX1MEN1KMT2AGAA
SCHEMBL2326093 1.00 ALDH1A1 (0.56) ALDH1A1EPHX1MEN1KMT2AGAA
SCHEMBL9398324 1.00 ALDH1A1 (0.56) ALDH1A1EPHX1MEN1KMT2AGAA
SCHEMBL25447123 1.00 ALDH1A1 (0.56) ALDH1A1EPHX1MEN1KMT2AGAA
SCHEMBL7333566 0.99 ALDH1A1 (0.54) ALDH1A1EPHX1MEN1KMT2AGAA
SCHEMBL7810127 0.99 ALDH1A1 (0.54) ALDH1A1EPHX1MEN1KMT2AGAA
SCHEMBL7337637 0.96 ALDH1A1 (0.52) ALDH1A1EPHX1MEN1KMT2AGAA
SCHEMBL2163641 0.93 CTRB1 (0.52) ALDH1A1MEN1KMT2AGAACTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250346602-A1 LACTAM SUBSTITUTED IMIDAZOPYRIDAZINE IL-17A MODULATORS AND USES THEREOF DICE ALPHA INC (US) 2025-11-13 US disclosed
US-20250154138-A1 Small Molecule IL-17A Modulators BEIGENE, LTD. (KY) 2025-05-15 US disclosed
WO-2023225664-A1 LACTAM SUBSTITUTED IMIDAZOPYRIDAZINE IL-17A MODULATORS AND USES THEREOF DICE ALPHA, INC. (US) 2023-11-23 WO disclosed
CN-116925060-A Method for synthesizing small molecule IL-17A modulator 百济神州(北京)生物科技有限公司 2023-10-24 CN disclosed
CN-116925064-A Method for synthesizing small molecule IL-17A modulator 百济神州(北京)生物科技有限公司 2023-10-24 CN disclosed
US-20220220152-A1 BIVALENT ANTAGONISTS OF INHIBITORS OF APOPTOSIS PROTEINS Hepagene Therapeutics (HK) Limited (HK) 2022-07-14 US disclosed
EP-3946607-A1 BIVALENT ANTAGONISTS OF INHIBITORS OF APOPTOSIS PROTEINS Hepagene Therapeutics (HK) Limited (HK) 2022-02-09 EP disclosed
EP-3341007-B1 MALT1 INHIBITORS AND USES THEREOF UNIV CORNELL (US) 2020-12-23 EP disclosed
WO-2020206000-A1 BIVALENT ANTAGONISTS OF INHIBITORS OF APOPTOSIS PROTEINS Hepagene Therapeutics (HK) Limited (CN) 2020-10-08 WO disclosed
US-10711036-B2 MALT1 inhibitors and uses thereof CORNELL UNIVERSITY (US) 2020-07-14 US disclosed
WO-2006024932-A1 2-AMINO-QUINAZOLINE DERIVATIVES USEFUL AS INHIBITORS OF B-SECRETASE (BACE) JANSSEN PHARMACEUTICA, N.V. (US) 2006-03-09 WO disclosed
WO-2006017844-A1 NOVEL 2-AMINO-QUINAZOLINE DERIVATIVES USEFUL AS INHIBITORS OF β-SECRETASE (BACE) JANSSEN PHARMACEUTICA, N.V. (BE) 2006-02-16 WO disclosed
WO-2006017836-A2 2-AMINO-QUINAZOLINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) JANSSEN PHARMACEUTICA, N.V. (BE) 2006-02-16 WO disclosed
US-6759420-B1 LOW MOLECULAR WEIGHT, FACTOR XA SPECIFIC BLOOD CLOTTING INHIBITORS WITHOUT SIDE EFFECTS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2004-07-06 US disclosed
EP-0721449-B1 INHIBITORS OF BETA-AMYLOID PROTEIN PRODUCTION MERRELL PHARMA INC (US) 2001-12-19 EP disclosed
EP-1150946-A1 ARYLALKANOYL DERIVATIVES, PROCESSES FOR THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM Aventis Pharma Deutschland GmbH (DE) 2001-11-07 EP disclosed
WO-2000040548-A1 ARYLALKANOYL DERIVATIVES, PROCESSES FOR THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2000-07-13 WO disclosed
US-5977074-A THERAPY FOR ALZHEIMER'S DISEASE MERRELL PHARMACEUTICALS, INC. (US) 1999-11-02 US disclosed
EP-0721449-A1 INHIBITORS OF $g(b)-AMYLOID PROTEIN PRODUCTION MERRELL PHARMACEUTICALS INC. (US) 1996-07-17 EP disclosed
WO-1995009838-A1 INHIBITORS OF β-AMYLOID PROTEIN PRODUCTION MERRELL PHARMACEUTICALS INC. (US) 1995-04-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250346602-A1 LACTAM SUBSTITUTED IMIDAZOPYRIDAZINE IL-17A MODULATORS AND USES THEREOF IL17A, IL15, IL18 ALDH1A1 392/4885EPHX1 3222/4885MEN1 4711/4885
US-20250154138-A1 Small Molecule IL-17A Modulators IL17A, IL23R, IL2 ALDH1A1 1401/4885EPHX1 3578/4885MEN1 4294/4885
US-10711036-B2 MALT1 inhibitors and uses thereof MALT1, BCL3, BCL6 ALDH1A1 2550/4885EPHX1 2780/4885MEN1 278/4885
US-20220220152-A1 BIVALENT ANTAGONISTS OF INHIBITORS OF APOPTOSIS PROTEINS BIRC5, BIRC2, BIRC3 ALDH1A1 4611/4885EPHX1 4222/4885MEN1 3609/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.